[HTML][HTML] GLP-1 receptor agonists: beyond their pancreatic effects
X Zhao, M Wang, Z Wen, Z Lu, L Cui, C Fu… - Frontiers in …, 2021 - frontiersin.org
Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists
(GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their …
(GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their …
[HTML][HTML] Glucagon-like peptide 1 (GLP-1)
TD Müller, B Finan, SR Bloom, D D'Alessio… - Molecular …, 2019 - Elsevier
Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …
Glucagon-like peptide 1 in health and disease
In healthy individuals, the incretin hormone glucagon-like peptide 1 (GLP1) potentiates
insulin release and suppresses glucagon secretion in response to the ingestion of nutrients …
insulin release and suppresses glucagon secretion in response to the ingestion of nutrients …
Perspectives in GLP-1 research: new targets, new receptors
The incretin hormone glucagon-like peptide-1 (GLP-1) binds to and activates its G-protein-
coupled-receptor GLP-1R to reduce glycaemia through the stimulation of insulin and …
coupled-receptor GLP-1R to reduce glycaemia through the stimulation of insulin and …
The extra‐pancreatic effects of GLP‐1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems
J Seufert, B Gallwitz - Diabetes, Obesity and Metabolism, 2014 - Wiley Online Library
The glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) exenatide, liraglutide and
lixisenatide have been shown to improve glycaemic control and beta‐cell function with a low …
lixisenatide have been shown to improve glycaemic control and beta‐cell function with a low …
GLP-1 receptor signaling: effects on pancreatic β-cell proliferation and survival
J Buteau - Diabetes & metabolism, 2008 - Elsevier
Type 2 diabetes is a metabolic disorder characterized by insulin resistance as well as a
progressive deterioration of pancreatic β-cell mass and function. Glucagon-like peptide 1 …
progressive deterioration of pancreatic β-cell mass and function. Glucagon-like peptide 1 …
GLP-1a: going beyond traditional use
LF Laurindo, SM Barbalho, EL Guiguer… - International Journal of …, 2022 - mdpi.com
Glucagon-like peptide-1 (GLP-1) is a human incretin hormone derived from the proglucagon
molecule. GLP-1 receptor agonists are frequently used to treat type 2 diabetes mellitus and …
molecule. GLP-1 receptor agonists are frequently used to treat type 2 diabetes mellitus and …
The ascending GLP-1 road from clinical safety to reduction of cardiovascular complications
DJ Drucker - Diabetes, 2018 - Am Diabetes Assoc
Glucagon-like peptide 1 (GLP-1) was originally identified as a gut-derived incretin hormone
that lowered glycemia through potentiation of glucose-dependent insulin secretion …
that lowered glycemia through potentiation of glucose-dependent insulin secretion …
GLP-1 based therapy for type 2 diabetes
DK Arulmozhi, B Portha - European journal of pharmaceutical sciences, 2006 - Elsevier
Type 2 diabetes mellitus is a major and growing health problem throughout the world.
Current treatment approaches include diet, exercise, and a variety of pharmacological …
Current treatment approaches include diet, exercise, and a variety of pharmacological …
Therapeutic strategies based on glucagon-like peptide 1
CF Deacon - Diabetes, 2004 - Am Diabetes Assoc
Glucagon-like peptide (GLP)-1 is an incretin hormone with potent glucose-dependent
insulinotropic and glucagonostatic actions, trophic effects on the pancreatic β-cells, and …
insulinotropic and glucagonostatic actions, trophic effects on the pancreatic β-cells, and …